J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance ...

Findings of reduced risks for mortality and major CVD suggest consideration of statins in all adults with type 2 diabetes, even in those with low short-term predicted CVD risk.

The target trial emulation study suggests rigid risk thresholds aren’t needed to steer statin use in this group.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate ...

Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced that the first patient has been ...

Art Limitless is a new programme within the BE OPEN Art online gallery tailored specifically to display the competitions, ...

For adults with type 2 diabetes (T2DM), statin initiation is associated with reductions in all-cause mortality and major ...

A large cohort study found that statins significantly reduce the risk of death and major cardiovascular events in adults with ...

Art Limitless is a new programme within the BE OPEN Art online gallery tailored specifically to display the competitions, webinars, master-classes ...

New research finds statins benefit adults with type 2 diabetes across all heart-risk levels, reducing deaths and serious ...

Cholesterol-lowering drugs (statins) reduce heart disease risk and death in adults with type 2 diabetes, making them a key ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.